Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
Text Size
6 studies found for:    17215530 [PUBMED-IDS]

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
1 Active, not recruiting Sorafenib Combined With Chemotherapy for Renal Collecting Duct Carcinoma
Condition: Renal Cell Carcinoma
Interventions: Drug: Sorafenib;   Drug: Gemcitabine;   Drug: Cisplatin
2 Active, not recruiting Level of Expression and Prognostic Value of CXCL4, CXCL4L1 and CXCR3 in Renal Cell Carcinoma
Conditions: Carcinoma;   Carcinoma Renal Cell;   Kidney Neoplasms;   Kidney Diseases;   Chemokines
Intervention: Biological: Biological sample
3 Completed Multicenter Dose-escalation Study of a Combination of Pazopanib and Bevacizumab in Patients With Metastatic Renal Cell Carcinoma or Others Advanced Solid Tumors
Conditions: Metastatic Renal Cell Carcinoma;   Advanced Refractory Solid Tumors Histologically or Cytologically Confirmed
Intervention: Drug: Association of Bevacizumab (BVC)+ Pazopanib (PZP)
4 Completed SORAVE - Sorafenib and Everolimus in Solid Tumors
Conditions: Unspecified Adult Solid Tumor, Protocol Specific;   Non-Small Cell Lung Cancer
Intervention: Drug: Combination of sorafenib and everolimus
5 Completed Combination of Temsirolimus and Bevacizumab in Patient With Metastatic Renal Cell Carcinoma
Condition: Metastatic Renal Cell Carcinoma
Interventions: Drug: Temsirolimus;   Drug: Bevacizumab;   Drug: Sunitinib;   Drug: Interferon alpha-2a
6 Completed
Has Results 		Study of BAY43-9006 in Patients With Unresectable and/or Metastatic Renal Cell Cancer
Condition: Carcinoma, Renal Cell
Interventions: Drug: Sorafenib (Nexavar, BAY43-9006);   Drug: Placebo
To Top

† Indicates status has not been verified in more than two years